Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

(2010) R. PANACCIONE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Continuing Medical Education Questions: February 2010

(2010) Kenneth R DeVault et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease

(2010) Cristina Nichita et al.   DIGESTION

Survey on the use of adalimumab as maintenance therapy in Crohnʼs disease in England and Ireland

(2010) Evangelos A. Russo et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

W1275 Long-Term Durability of Response to Adalimumab Treatment in Crohn's Disease

(2010) Maria Chaparro et al.   GASTROENTEROLOGY

W1313 Adalimumab for Luminal and Perianal Crohn's Disease in Real Practice: A Long-Term Multicenter Study of Effectiveness, Safety and Predictors of Response

(2010) Jose Ignacio Fortea Ormaechea et al.   GASTROENTEROLOGY

W1312 Long Term Efficacy of the Second Biologic in the Management of Crohn's Disease. A Retrospective Survey on an English- Irish Cohort

(2010) Evangelos Russo et al.   GASTROENTEROLOGY

W1325 Persistency Equals Efficacy in Adalimumab Patients: Preliminary Report of a Large Single Site Experience

(2010) Douglas C. Wolf et al.   GASTROENTEROLOGY

W1335 Previous Non-Response to Infliximab Predicts Early Dose-Escalation in Adalimumab Treated Crohn's Disease Patients

(2010) Evelien Bultman et al.   GASTROENTEROLOGY

Adalimumab for Crohnʼs disease in clinical practice at Mayo clinic: The first 118 patients

(2010) Jason M. Swoger et al.   INFLAMMATORY BOWEL DISEASES

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

(2010) William J. Sandborn et al.   INFLAMMATORY BOWEL DISEASES

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

(2010) A. Dignass et al.   Journal of Crohns & Colitis

The potential for disease modification in Crohn's disease

(2010) G. Van Assche et al.   Nature Reviews Gastroenterology & Hepatology

Tratamiento de inducción y mantenimiento con adalimumab en la enfermedad de Crohn: un estudio abierto

(2010) N. López Palacios et al.   REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies

(2009) M. ALLEZ et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prospective Evaluation of Anti-Tumor Necrosis Factor Therapy Guided by Magnetic Resonance Imaging for Crohn's Perineal Fistulas

(2009) Siew C Ng et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial

(2009) Jean-Frédéric Colombel et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn’s Disease

(2009) Joel R Rosh et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease

(2009) Franca Viola et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Influence of Phenotype at Diagnosis and of Other Potential Prognostic Factors on the Course of Inflammatory Bowel Disease

(2009) M J L Romberg-Camps et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab Treatment in Children with Refractory Crohn’s Disease

(2009) Yoram Rosenbach et al.   DIGESTIVE DISEASES AND SCIENCES

W1093 Predictors and Timing of Adalimumab (ADA) Dose Escalation in Patients with Crohn's Disease (CD)

(2009) Russell D. Cohen et al.   GASTROENTEROLOGY

W1102 Anti-TNF Therapy for Crohn's Disease: Predictors of Dose Escalation and Early Discontinuation By 1 Year of Therapy

(2009) Amar S. Naik et al.   GASTROENTEROLOGY

W1225 Adalimumab in a Clinical Practice - Experience with Human Anti TNF-α Therapy in Tertiary Clinical Center

(2009) Martin Bortlik et al.   GASTROENTEROLOGY

S1049 Adalimumab in the Treatment of Active Luminal and Perianal Crohn's Disease: A Single Center Experience in 100 Patients

(2009) Fernando Rizzello et al.   GASTROENTEROLOGY

S1040 Dosage Pattern of Adalimumab in Real-World Clinical Practice and Predictors of Dosage Increase in Patients with Crohn's Disease in the US

(2009) Edward V. Loftus et al.   GASTROENTEROLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease

(2009) Andrea Cassinotti et al.   INFLAMMATORY BOWEL DISEASES

P042 - 2 year follow up of adalimumab therapy in patients with Crohn's disease

(2009) K. Kemp et al.   Journal of Crohns & Colitis

Safety and Efficacy of Adalimumab in Pediatric Patients With Crohn Disease

(2009) Matthew J Wyneski et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

(2008) R. L. WEST et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up

(2008) C. W. LEES et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008)

(2008) G. T. HO et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience

(2008) A. OUSSALAH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials

(2008) Laurent Peyrin–Biroulet et al.   Clinical Gastroenterology and Hepatology